The Open Targets Blog

MAY 9, 2024

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Different predicted functional consequences of pharmacogenetics variants from the PharmGKB data. What's new?

Pharmacogenetics 72

Pharmacogenetics Drugs Therapies Disease 72

ASPET

SEPTEMBER 16, 2024

GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact BBB.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Efficacy of radiosensitizers for brain tumors may be influenced by a lack of effective drug delivery across the blood-brain barrier (BBB).

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100